



INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (IJPRD)

Platform for Pharmaceutical Researches & Innovative Ideas

www.ijprd.com

DEVELOPMENT AND OPTIMIZATION OF FAMOTIDINE GASTRORETENTIVE DRUG DELIVERY SYSTEM

Bharati V. Bakde^{1*}, Madhuri Channawar¹, Anil V. Chandewar¹, B. Mishra²

¹Pataldhamal Wadhvani College of Pharmacy Yavatmal -442001, India

²Banaras Hindu University, Varanasi, UP, India

ABSTRACT

Famotidine (FMT) gastroretentive (GR) controlled release system was formulated to increase gastric residence time leading to improved drug bioavailability. Novel combinations of carbopol 940 P, Psyllium Husk, Rosin and Eudragit RLPO were selected for the present study. Floating lag time (Flag) and diffusion exponent as dependent variables revealed that the amount of carbopol 940 P, Psyllium Husk, Rosin, Eudragit RLPO have a significant effect ($p < 0.05$) on famotidine release and Flag. FMTGR tablets were prepared and evaluated for mass, thickness, hardness, friability, drug content and floating property. Tablets were studied for dissolution for 12 h and exhibited controlled release of FMT with floating for 12 h. The release profile of the optimized batch C9 fitted zero-order kinetics ($R^2 = 0.954$).

Correspondence to Author



Bharati V. Bakde

Pataldhamal Wadhvani College
of Pharmacy Yavatmal,,
Maharashtra, India.

Email

bakdebharati@rediffmail.com

Key Words

Famotidine, gastroretention,
floating tablets, release kinetics,
controlled release

INTRODUCTION

Gastric retention will provide advantages such as delivery of drugs with narrow absorption windows in the small intestinal region, namely proximal parts of the gastrointestinal tract (stomach and/or duodenum). Pharmaceutical dosage for FMT which remain in stomach for a prolonged period of time after oral administration and release the active ingredient in a controlled manner are important for the delivery of a wide variety of drugs (1-3).

Famotidine (FMT) is a H₂-receptor Antagonist, Antiulcerative. Orally administered famotidine is incompletely absorbed from gastrointestinal tract, and it undergoes minimal first-pass metabolism. The main limitations of the therapeutic effectiveness of Famotidine is its low bioavailability (20 to 66%), short biological half life (~3 to 4 h). Since the half-life of FMT is ~3 to 4 h, multiple doses are needed to maintain a constant plasma concentration for a good therapeutic response and improved patient compliance. FMT is recommended for the short-term treatment of acute duodenal ulcer, gastric ulcer and gastroesophageal reflux and soluble in stomach pH. It is therefore a suitable candidate for gastroretentive floating monolithic system (4).

The present study involves the design and optimization of a novel gastroretentive, floating, swellable, controlled release tablet by combining three polymers with different concentrations: carbopol 940 P-gel forming agent, Psyllium Husk, Rosin and Eudragit RLPO – rapidly hydrating, rate controlling polymers. Furthermore sodium bicarbonate (SBC) as a gas generating agent were also used. The combined effect of these polymers on the floating behaviour and on in vitro release pattern of the FMT has also been evaluated. (5)

EXPERIMENTAL

MATERIALS

Famotidine was received as a gift sample from zim laboratories, India. Psyllium Husk, Rosin were received as a gift sample from Zim Laboratories, Nagpur and Eudragit RLPO was received as a gift sample from

Colorcon asia pacific, goa ,india. SBC, talc and Magnesium Stearate (FMT) was purchased from S.D. Fine-Chem Ltd., India. All the other chemicals used were of analytical grade.

METHODS

Calibration curves of FMT were determined in 0.1 M HCl at $\lambda = 266 \text{ nm}$ ($R = 0.9932$), using a UV-Visible spectrophotometer (Shimadzu, Japan). The calibration curve in 0.1 M HCl was used for dissolution studies.

Preparation of FMTGR tablets

FMTGR tablets were prepared according to the composition of optimized batches (Table I) FMTGR tablets (300 mg) were prepared by the direct compression method. Initially, all ingredients were sieved through sieve no. 80, weighed and mixed for 10 min. The drug was mixed with carbopol 940 P (CP), Psyllium Husk (PH), Rosin (RO), Eudragit RLPO (EU), SBC, talc and MCC. Finally, the FMT was added as a lubricant and mixed for additional 2–3 min. Tablets were compressed on a tableting machine (10 stations, Cadmach Machinery, Mumbai, India) fitted with a 10mm circular shaped standard concave punch. (6)

Fourier Transform Infrared (FTIR) Spectroscopy

IR spectrum of drug was measured in the solid state (Drug: Excipient ratio 1:1) as potassium bromide dispersion. The bands have been assigned for drug, polymer and formulations. The powder of mixture of drug and polymer were mixed with potassium bromide (Merck) in 1:100 proportions and dried at 40°C. The mixture was compressed to a 12 mm semi transparent disk by applying a pressure of 10 tons (KBr press, tsi, Mumbai) for 2 min. The FTIR spectra over the wavelength range 4000–400 cm⁻¹ were recorded using a FTIR spectrometer (8400S, Shimadzu, Japan). (7)

Characterization of FMTGR tablets

The prepared FMTGR tablets were tested for physical characteristics, viz., weight variation, thickness (measured using a Screw gauge), hardness (measured with a hardness tester, Monsanto, Dolphin Ltd., Mumbai, India) and friability (determined using a Roche friabilator, Mumbai, India).(8)

Table I. FMTGR tablet composition

| Formulation batch | (CP) (%) | (SA) (%) | (RO) (%) | (EU) (%) | (MCC) (%) |
|-------------------|----------|----------|----------|----------|-----------|
| C1 | 20.0 | - | - | - | 59.4 |
| C2 | 26.6 | - | - | - | 52.8 |
| C3 | 33.3 | - | - | - | 46.0 |
| C4 | 40.0 | - | - | - | 39.4 |
| C5 | 33.3 | 6.6 | - | - | 39.4 |
| C6 | 26.6 | 13.3 | - | - | 39.4 |
| C7 | 33.3 | - | 6.6 | - | 39.4 |
| C8 | 26.6 | - | 13.3 | - | 39.4 |
| C9 | 33.3 | - | - | 6.6 | 39.4 |
| C10 | 26.6 | - | - | 13.3 | 39.4 |
| C11 | - | 40.0 | - | - | 39.4 |
| C12 | - | - | 40.0 | - | 39.4 |
| C13 | - | - | - | 40.0 | 39.4 |

CP – carbopol 940 P, PH – Psyllium Husk, RO – Rosin, EU – Eudragit RLPO.

All batches contain 3 % Talc, 16.6 % SBC and 1 % magnesium stearate.

Total tablet mass is 300.0 mg.

Drug content

Accurately weighed FMTGR tablets (10 tablets) were crushed to form a fine powder. An accurately weighed quantity equivalent to 40 mg of FMT was transferred to a 100-mL volumetric flask. To this, 50 mL 0.1 N HCl was added and sonicated for 15 min. Volume was made up to the mark with 0.1 N HCl. The solution was filtered through a 0.45-mm filter and 1 mL of this solution was diluted to 50 mL with 0.1 N HCl. Absorbance was measured at 266 nm. (9)

In vitro dissolution studies

The release rate of FMTGR tablets (n = 3) was determined with a USP dissolution apparatus- II (paddle method) using 100 rpm speed and 900 mL of 0.1 N HCl as dissolution medium at 37 ± 0.5 °C (11). A sample 5 mL of the solution) was withdrawn from the dissolution apparatus (DBK Instruments Ltd., Mumbai, India) at regular time intervals up to 12 h (, 2, 4, 6, 8, 10 and 12 h) and replaced with the same volume of fresh dissolution medium. The samples were filtered through a 0.45-mm

membrane filter and diluted to a suitable concentration with 0.1 N HCl, and the absorbance of these solutions was measured at 266 nm. Cumulative percentage of drug release was calculated using the equation obtained from a standard curve. (10)

In vitro buoyancy studies

The *in vitro* buoyancy studies were performed by measuring the floating lag times. The tablets were placed in a 100-mL beaker containing 0.1 M HCl. The time required for the tablet to rise to the surface and float was defined as the floating lag time (Flag). (11)

RESULTS AND DISCUSSION

Physical characterization of the tablets

Tablet weight of all the formulations was found to be 300.0 ± 15.0 mg. Tablet thickness was found to be 4.3 ± 0.1 mm. The hardness of the formulation was 5 to 6 kg/cm², indicating satisfactory mechanical strength. Percentage mass loss in the friability test was 0.2 to 0.5 % in all cases, which was an indication of good mechanical resistance of the tablet. Tablets of all the prepared batches containing FMT were found to be within 100.0 ± 5.0 % of the labelled content, indicating content uniformity of the prepared formulations.

FTIR spectroscopy study

Physical mixture of drug and polymer was characterized by FTIR spectral analysis for any physical as well as chemical alteration of the drug characteristics. It can be concluded that there was no interference in the functional group as the principle peaks of the FMT was found to be unaltered in the drug-polymer physical mixtures, indicating they were compatible.

In vitro buoyancy studies

The results of in vitro buoyancy studies showed quick floating of the tablet within 2 min after placing the tablet in dissolution medium. Studies showed that no single polymer individually was sufficient to produce buoyancy and integrity of the tablet. Flag varied between 45 s to 15 min (Table II). Buoyancy mainly depended upon the quantity of SBC. SBC of 16.6 % was found optimal with optimum integrity and controlled release profile of the drug from the tablet. CP produces swelling of the tablet while SBC has the ability to generate gas in the presence of hydrochloric acid, which gets entrapped in the tablet. This leads to reduction in the density of the tablet, thereby producing floating.

In vitro dissolution studies

By using pharmacokinetic parameters of famotidine, the theoretical drug release for a 12-h dosage form was calculated. An effective drug plasma concentration was maintained when the sustained release formulation released the required quantity of drug with predetermined kinetics. To achieve this, floating tablets should be formulated so that they release the drug in a predetermined and reproducible manner.

The release of famotidine from effervescent floating tablets was analyzed by plotting the cumulative percent drug release against time. The in vitro drug release studies revealed that formulations C1, C2, C3 and C4 (Fig. 1) containing 20, 26, 33 and 40% Carbopol 940 P respectively, were able to sustain the drug release for 8, 10 and 12 h, respectively. Floating lag time was 127 seconds; total buoyancy was 8 to 12 h and tablet integrity was good for Carbopol 940 P formulations.

Drug release profiles of formulations C5 to C8 containing 33 % Carbopol 940 P and 6.6 and 13.2 % of Psyllium Husk (C5 and C6) and Rosin (C7 and C8) each, are shown in Fig. 2. For C5 and C7, 100 % of the drug was

released after 12 hours. 100 % of drug was released from formulations C6 and C8, respectively, after 10 h. Formulation C1, C2, C6 and C8 underwent swelling and erosion, resulting in faster drug release. In C3, 33 % of Carbopol 940 P was sufficient to sustain the drug release for 12 h. On increasing the quantity of Carbopol 940 P up to 40 %, the release of the drug was too slow and only 89 % of the drug was released after 12 h. Drug release profiles of formulations C9-F13, composed of Carbopol 940 P and eudragit RLPO, Psyllium Husk, Rosin and eudragit RLPO alone are shown in Fig. 3. The percentage of drug released from these formulation C9 was 98 after 12 h. The percentage of drug released from these formulations was 100% for C10- C13 after 10 h, 4 h, 6h and 4h respectively. This variation was considered to be due to different polymers and their concentrations. Release of the drug was faster with Psyllium Husk, Rosin and eudragit RLPO may be due to lower gel strength, less entanglement and smaller diffusion path length compared to Carbopol 940 P. In all the formulations, polymer concentration greatly affected the release of the drug. The drug release rate was inversely proportional to the polymer concentration present in the matrix. It was observed that when the polymer concentration was increased, the drug release rate decreased.




Fig. 1. FMTGR tablets dissolution profile of batches C1 to C4. Mean \pm SD, n = 3.




Fig. 2. FMTGR tablets dissolution profile of batches C5 to C8. Mean \pm SD, n = 3




Fig. 3. FMTGR tablets dissolution profile of batches C9 to C13. Mean \pm SD, n = 3

Drug release kinetics

The results of kinetic models for famotidine release from floating matrix tablets are shown in Table II. The coefficient of determination (R^2) was used as indicator of the best fitting for each of the models considered. To explore the mechanism of drug release, the results of in vitro data were fitted into the first-order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas models. The results revealed that all formulations of floating matrix tablets fitted best the zero-order model except formulations C5, C6, C10 – C13. C5 and C6 were fitted best for the Higuchi and First Order models.

The release profile of the optimized batch C9 was fitted best to the zero-order ($R^2 = 0.954$) Formulation C9 zero order release profile and least floating lag time of 45 s; for these reasons, C9 was considered the best among all the formulations.(10)

| Batch Code | R^2 | | | n value |
|------------|------------|-------------|---------|---------|
| | Zero order | First order | Higuchi | |
| C1 | 0.983 | 0.889 | 0.847 | 1.17 |
| C2 | 0.984 | 0.695 | 0.843 | 1.18 |
| C3 | 0.983 | 0.964 | 0.969 | 0.76 |
| C4 | 0.982 | 0.981 | 0.971 | 0.73 |
| C5 | 0.931 | 0.786 | 0.992 | 0.60 |
| C6 | 0.956 | 0.997 | 0.9899 | 0.63 |
| C7 | 0.977 | 0.955 | 0.881 | 1.32 |
| C8 | 0.997 | 0.814 | 0.906 | 1.05 |
| C9 | 0.954 | 0.931 | 0.848 | 1.31 |

R^2 – coefficient of determination, n – release exponent of Korsmeyer-Peppas

CONCLUSIONS

The present study involved the design of a novel gastroretentive floating and swellable, controlled-release, tablet of FMT. Its comprised the release-rate-controlling hydrophilic polymers, in different

concentrations, a release modulator and a gas generating agent. Upon administration, the FMTGR tablet was hydrated and swelled rapidly due to imbibition of the gastrointestinal fluid; subsequent gas generation helped the system buoyancy and the desired

release profile. Optimized batch formulation C9 showed buoyancy with Flag time less than one min (48 s) and remained floating for 12 h. Minimum floating time and higher percentage of swelling of the C9 formulation is required to increase its residence time in the stomach and eventually improve the extent of bioavailability. The present study confirmed the test of the suitability of gastroretentive platform technology developed for the FMTGR tablet without changing any excipients and process parameters. The optimized batch C9 tablet, prepared using novel combinations of CP, RO and SBC, can be successfully employed as a twice-a-day oral controlled release drug delivery system.

ACKNOWLEDGEMENTS

The authors are thankful to Samed Labs, India, for their generous gift sample of tizanidine hydrochloride. The authors also thank Danmed Pharmaceuticals, India, for generous gift samples of HPMC grade polymers.

REFERENCES

1. S. Arora, J. Ali, A. Ahuja, R. K. Khar and S. Baboota, Floating Drug Delivery Systems: A Review, *AAPS PharmSciTech.* 6 (3) 47- (2005)
 2. N. Rouge, P. Buri and E. Doelker, Drug absorption sites in the gastrointestinal tract and dosage for site specific delivery, *Int. J. Pharm.* 136 (1996) 117-139.
 3. A. Streubel, J. Siepmann and R. Bodmeier, Gastroretentive drug delivery system, *Expert Opin Drug Deliv.* 3(2) (2006) 217-233
 4. A. Mohamed Al-Omar and A. M. Al-Mohizea, Profiles of Drug Substances, Excipients, and Related Methodology, *Famotidine*, 34, pp. 116-125.
 5. K.Gnanaprakash, K. ChandhraShekhar and C. Chetty, Floating tablets of Famotidine with natural polymer: An approach for gastric treatment, *J. Pharm. Sci. & Res.* 2 (10) (2010) 657-662
 6. S. Boldhane and B. Kuchekar, Development and optimization of Famotidine gastroretentive drug delivery system, *Acta Pharm.* 60 (2010) 415–425.
 7. K. Someshwar et al.: Formulation and evaluation of effervescent floating tablets of famotidine, *Acta Pharm.* 61 (2011) 217–226.
 8. D. Jagadeesh Kumar, A. Hindustan, C. Anuradha, S. Chitta, K. Reddy, R. Savithri, Dual acting oral floating matrix tablets of ranitidine hydrochloride, *International Journal of Applied Biology and Pharmaceutical Technology* 1(2) - (2010)
 9. L. Whitehead, J. Fell, J. Collett, Sharma H. and A. Smith Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. *J Control Release*, 30 - (1998) 3-12.
 10. K. Someshwar¹, T. Ramarao and K. Kumar, Formulation and evaluation of effervescent floating tablets of tizanidine hydrochloride, *Acta Pharm.* 61 (2011) 217–226
- R. Patel and J. Patel. Development and evaluation of *in situ* novel intragastric controlled-release formulation of hydrochlorothiazide. *Acta Pharm.*, 61, (2011) 73–78
